Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy.

作者: R. A. Bernert , J. L. Logan , Y.-H. H. Lien , S. O'brien

DOI: 10.1681/ASN.V891483

关键词:

摘要: Posttransplant lymphoproliferative disorder (PTLD) is one of the major complications immunosuppressive therapy. PTLD strongly associated with Epstein-Barr virus (EBV). It believed that EBV-infected B cells proliferate in an unchecked manner due to suppression cytotoxic T and elevation cell-promoting cytokines. There no consensus on treatment other than reduction We report a case monoclonal confined lymph nodes. The patient did not initially respond immunosuppression, oral acyclovir, intravenous immunoglobulin injection. She subsequently responded when subcutaneous injections interferon alfa (5 million U) were given three times week. received 3-mo course remained remission 12 mo after treatment. Her graft function was well maintained, cyclosporin A restarted 2 achieving remission. clinical manifestations, risk factors, pathogenesis, PTLD, as previously reported cases treated interferon, reviewed. On basis results presented here, it appears may be useful treating there need for further trials.

参考文章(31)
T. M. Habermann, C. V. Paya, C. G.A. McGregor, R. H. Wiesner, J. G. Strickler, R. C. Daly, W. F. Marshall, J. A. Velosa, R. C. Walker, Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. Journal of Heart and Lung Transplantation. ,vol. 14, pp. 214- 221 ,(1995)
LJ Swinnen, GM Mullen, TJ Carr, MR Costanzo, RI Fisher, Aggressive treatment for postcardiac transplant lymphoproliferation Blood. ,vol. 86, pp. 3333- 3340 ,(1995) , 10.1182/BLOOD.V86.9.3333.BLOODJOURNAL8693333
Douglas W. Hanto, John S. Najarian, George Klein, Ari K. Saemundsen, Kiyoshi Sakamoto, John L. Sullivan, Richard L. Simmons, Glauco Frizzera, David T. Purtilo, Clinical Spectrum of Lymphoproliferative Disorders in Renal Transplant Recipients and Evidence for the Role of Epstein-Barr Virus Cancer Research. ,vol. 41, pp. 4253- 4261 ,(1981)
V Leblond, L Sutton, R Dorent, F Davi, M O Bitker, J Gabarre, F Charlotte, J J Ghoussoub, C Fourcade, A Fischer, Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. Journal of Clinical Oncology. ,vol. 13, pp. 961- 968 ,(1995) , 10.1200/JCO.1995.13.4.961
Vicki A. Morrison, David L. Dunn, J.Carlos Manivel, K.J. Gajl-Peczalska, Bruce A. Peterson, Clinical characteristics of post-transplant lymphoproliferative disorders The American Journal of Medicine. ,vol. 97, pp. 14- 24 ,(1994) , 10.1016/0002-9343(94)90043-4
D.H Crawford, J.A Thomas, G Janossy, P Sweny, O.N Fernando, J.F Moorhead, J.H Thompson, EPSTEIN BARR VIRUS NUCLEAR ANTIGEN POSITIVE LYMPHOMA AFTER CYCLOSPORIN A TREATMENT IN PATIENT WITH RENAL ALLOGRAFT The Lancet. ,vol. 315, pp. 1355- 1356 ,(1980) , 10.1016/S0140-6736(80)91800-0
Douglas W. Hanto, Glauco Frizzera, Kazimiera J, Gajl-Peczalska, Kiyoshi Sakamoto, David T. Purtilo, Henry H. Balfour, Richard L. Simmons, John S. Najarian, Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. The New England Journal of Medicine. ,vol. 306, pp. 913- 918 ,(1982) , 10.1056/NEJM198204153061506
SANDRA M. COCKFIELD, JUTTA K. PREIKSAITIS, LAURENCE D. JEWELL, ANDNOLLAIG A. PARFREY, Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation. ,vol. 56, pp. 88- 96 ,(1993) , 10.1097/00007890-199307000-00016
Akio Urabe, Interferons for the Treatment of Hematological Malignancies Oncology. ,vol. 51, pp. 137- 141 ,(1994) , 10.1159/000227328